Ovation Science Files Provisional US Patent for Transdermal Delivery of Cannabinoids CBD and THC


Ryan Allway

February 25th, 2020

News


VANCOUVER, BC / ACCESSWIRE / February 25, 2020 / Ovation Science Inc. (CSE:OVAT) (“Ovation” or the “Company”), a personal care and topical cannabis product development company with a patented skin delivery technology, today announced that it has filed a provisional patent with the U.S. Patent and Trademark Office (USPTO) for its highly effective transdermal delivery of cannabinoids CBD and THC; titled “Composition and Method for Transdermal Delivery of Cannabidiol (CBD) and D9-Tetrahydrocannabinol (THC).”

Ovation is focused on developing exceptional topical and transdermal products for the global marketplace. Ovation’s provisional patent application sets a priority date and protects the Company’s invention of a novel and improved composition and method of a transdermal delivery system allowing delivery of cannabinoids through the skin at therapeutic levels. Transdermal delivery is a more efficient method than oral (edibles) or inhalation (smoking or vaping) as it avoids metabolism of the majority of the cannabinoids by the first pass through the liver and delayed onset, which is the case for oral dosage forms, and damage to the lungs by inhalation. This patent filing is an addition to the current patent protection that already covers Ovation’s delivery system. Once granted, this patent would extend Ovation’s patent protection for transdermal delivery to 2040.

“Today’s announcement builds on Ovation’s licensed patent portfolio with a patent application specifically focused on transdermal delivery. We continually leverage our expertise in topical and transdermal delivery of CBD and THC in order to develop these highly innovative products. This patent application adds another layer of protection to our invention and an advantage over other delivery methods,” said Terry Howlett, President of Ovation. “We are also committed to providing consumers with products backed by science as a reassurance that our products are highly effective in their delivery of cannabinoids.”

Ovation’s transdermal products are applied topically to the skin and absorbed through the skin into the bloodstream (into the body systemically) over time. Ovation’s invention does not use a patch or other device to accomplish this.

What makes Ovation’s product different than any other topical cannabis products on the market is its superior delivery of CBD and THC using its patented skin delivery technology Invisicare®. Invisicare is a drug delivery technology with over twenty years of research and development in the pharmaceutical industry; specifically, dermatology and is patented in eleven countries. Ovation has leveraged this delivery system by developing two product lines: Invibe MD and ARLO CBD Beauty; both using Invisicare and hemp-derived CBD. All Ovation products are thoroughly tested to ensure product stability and to validate that they deliver the stated amount of cannabinoids.

To learn more about Ovation Science, please visit:

www.ovationscience.com for corporate information

www.InvibeMD.com or connect with Invibe MD on Facebook, Instagram and Twitter.

www.ArloCBDBeauty.com or connect with ARLO on Facebook, Instagram and Twitter.

Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Ovation does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

About Ovation Science Inc.

Ovation Science Inc. is a research and development company that develops topical and transdermal cannabis and hemp formulations made with patented Invisicare® skin delivery technology. The technology enhances the delivery of cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC) to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation’s management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal cannabis products incorporating CBD, THC and combination products along with a line of anti-aging / beauty products made with CBD. Ovation’s business model is to develop and market its two product lines ARLO CBD Beauty and Invibe MD, our health and wellness line, as well as continuing to out-license its topical and transdermal formulations to cannabis companies globally. Ovation formulated CBD and THC products are marketed in Nevada in state-approved dispensaries by its US licensee with additional states being added. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. Ovation has offices in Vancouver, BC Canada and Las Vegas, Nevada, USA. Ovation trades on the CSE under the symbol OVAT. Visit our website www.ovationscience.com.

Forward-Looking Statements

The information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Ovation Science Inc. cautions that all forward-looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.’s control.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Contact:

FOR INVESTOR RELATIONS:

Doug Kerr:
[email protected]
Phone 604.315.4400

FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES:

Doreen McMorran:
[email protected]
Phone: 604.283.0903 ext. 4

SOURCE: Ovation Science Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading